First-in-human evaluation of infinitopes’ therapeutic platform

First IBAT inhibitor for PBC cholestatic pruritus

Designation supports pivotal trials for emerging candidates

Phase 3 data show strong benefit for two therapies

First patient enrolled in pivotal coronary study

European regulators move closer to approving option for young male patients

New service strengthens UK access to advanced multiomics support

Where the future of workplace wellbeing takes centre stage

Jideytro offers option for previously treated patients

Designation supports development of novel orexin therapy